Cargando…
A third dose of the unmodified COVID-19 mRNA vaccine CVnCoV enhances quality and quantity of immune responses
A third vaccine dose is often required to achieve potent, long-lasting immune responses. We investigated the effect of three 8-μg doses of CVnCoV, CureVac’s severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine candidate containing sequence-optimized unmodified mRNA encoding the spike...
Autores principales: | Lenart, Klara, Hellgren, Fredrika, Ols, Sebastian, Yan, Xianglei, Cagigi, Alberto, Cerveira, Rodrigo Arcoverde, Winge, Inga, Hanczak, Jakub, Mueller, Stefan O., Jasny, Edith, Schwendt, Kim, Rauch, Susanne, Petsch, Benjamin, Loré, Karin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9535876/ https://www.ncbi.nlm.nih.gov/pubmed/36217434 http://dx.doi.org/10.1016/j.omtm.2022.10.001 |
Ejemplares similares
-
Unmodified rabies mRNA vaccine elicits high cross-neutralizing antibody titers and diverse B cell memory responses
por: Hellgren, Fredrika, et al.
Publicado: (2023) -
Author Correction: Unmodified rabies mRNA vaccine elicits high cross-neutralizing antibody titers and diverse B cell memory responses
por: Hellgren, Fredrika, et al.
Publicado: (2023) -
mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents
por: Rauch, Susanne, et al.
Publicado: (2021) -
Cell targeting and immunostimulatory properties of a novel Fcγ-receptor-independent agonistic anti-CD40 antibody in rhesus macaques
por: Yan, Xianglei, et al.
Publicado: (2023) -
CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2
por: Hoffmann, Donata, et al.
Publicado: (2021)